Benefit of cetuximab addition to a platinum-fluorouracil-based chemotherapy according to KRAS-LCS6 variant in an unselected population of recurrent and/or metastatic head and neck cancers.
Vianney BastitNicolas Bon-MardionJean-Michel PicquenotVinciane RainvilleCristian MoldovanArnaud FrançoisAgnès LoebSébastien ThureauDorel ManuFabrice JardinJean-Paul MarieFréderic Di FioreFlorian ClatotPublished in: European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery (2018)
Our results suggest that PFU + Cx combination may be effective in unselected population of R/MHNC regardless the KRAS-LCS6 variant status.